Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes

Clinical Nutrition

Volumn 28, Issue 3, 2009, Pages 278-284

  Obara, Kuniaki ^a   Mizutani, Mai ^b   Hitomi, Yoshitaka ^b   Yajima, Hiroaki ^b   Kondo, Keiji ^b  

^a Kirin Company   (Japan)

^b KIRIN HOLDINGS CO LTD   (Japan)

Author keywords

Diabetes; Hops; Hyperglycemia; Isohumolone; Obesity

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HUMULUS LUPULUS EXTRACT; ISOHUMULONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; JAPANESE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL;

ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRY; ANTI-OBESITY AGENTS; BEER; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CAPSULES; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67349257962     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2009.03.012     Document Type: Article

References (25)

1. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23 (2006) 469-480
2. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
3. Ludvik B., Neuffer B., and Pacini G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care 27 2 (2004 Feb) 436-440
4. Diepvens K., Kovacs E.M., Nijs I.M., Vogels N., and Westerterp-Plantenga M.S. Effect of green tea on resting energy expenditure and substrate oxidation during weight loss in overweight females. Br J Nutr 94 6 (2005 Dec) 1026-1034
5. Nagao T., Hase T., and Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 15 6 (2007 Jun) 1473-1483
6. Ludwig N. Abriss der Bierbrauerei. 7th ed. (2004), WILEY-VCH Verlag, Weinheim
7. Yajima H., Ikeshima E., Shiraki M., Kanaya T., Fujiwara D., Odai H., et al. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator - activated receptor α and γ and reduce insulin resistance. J Biol Chem 279 (2004) 33456-33462
8. Yajima H., Noguchi T., Ikeshima E., Shiraki M., Kanaya T., Tsuboyama-Kasaoka N., et al. Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents. Int J Obes (Lond) 29 8 (2005 Aug) 991-997
9. Miura Y., Hosono M., Oyamada C., Odai H., Oikawa S., and Kondo K. Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice. Br J Nutr 93 4 (2005 Apr) 559-567
10. Shimura M., Hasumi A., Minato T., Hosono M., Miura Y., Mizutani S., et al. Isohumulones modulate blood lipid status through the activation of PPAR alpha. Biochim Biophys Acta 1736 1 (2005 Sep 5) 51-60
11. Namikoshi T., Tomita N., Fujimoto S., Haruna Y., Ohzeki M., Komai N., et al. Isohumulones derived from hops ameliorate renal injury via an anti-oxidative effect in Dahl salt-sensitive rats. Hypertens Res 30 2 (2007 Feb) 175-184
12. Takeshi K., Shoichi N., Jo S., Yasunori K., Yasuhiko I., Masashi K., et al. Report of the committee of Japan diabetes society on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 42 5 (1999) 385-404
13. Tokunaga K., Matsuzawa Y., Ishikawa K., and Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 7 5 (1983) 437-445
14. Spiegelman B.M. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
15. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 106 (2000) 467-472
16. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor γ have depot specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
17. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., and Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24 (2001) 308-315
18. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
19. Raskin P., Rappaport E.B., Cole S.T., Yan Y., Patwardhan R., and Freed M.I. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43 (2000) 278-284
20. Nolan J.J., Jones N.P., Patwardhan R., and Deacon L.F. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17 (2000) 287-294
21. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
22. Despres J.-P., Lemieux I., Salomon H., and Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12 week randomized trial. J Intern Med 251 (2002) 490-499
23. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al., FIELD Study Investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
24. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 9548 (2006 Nov 11) 1660-1672
25. Van Gaal L., Pi-Sunyer X., Després J.P., McCarthy C., and Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl. 2 (2008 Feb) S229-S240